Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9005232 | Clinical Therapeutics | 2005 | 11 Pages |
Abstract
In these patients with primary hypercholesterolemia, EZE 10 mg/d added to ongoing SIMVA treatment for 48 weeks had a favorable safety and tolerability profile and was more efficacious than SIMVA monotherapy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
MD Masana, MD Mata, MD Gagné, BS Sirah, PhD Cho, PhD Johnson-Levonas, PhD Meehan, MS Troxell, MD Gumbiner, Ezetimibe Study Group Ezetimibe Study Group,